542 related articles for article (PubMed ID: 34469765)
1. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.
Joseph P; Roshandel G; Gao P; Pais P; Lonn E; Xavier D; Avezum A; Zhu J; Liu L; Sliwa K; Gamra H; Bangdiwala SI; Teo K; Diaz R; Dans A; Lopez-Jaramillo P; Prabhakaran D; Castellano JM; Fuster V; Rodgers A; Huffman MD; Bosch J; Dagenais GR; Malekzadeh R; Yusuf S;
Lancet; 2021 Sep; 398(10306):1133-1146. PubMed ID: 34469765
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.
Bahiru E; de Cates AN; Farr MR; Jarvis MC; Palla M; Rees K; Ebrahim S; Huffman MD
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD009868. PubMed ID: 28263370
[TBL] [Abstract][Full Text] [Related]
3. Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis.
Dagenais GR; Pais P; Gao P; Roshandel G; Malekzadeh R; Joseph P; Yusuf S
Heart; 2023 Aug; 109(18):1372-1379. PubMed ID: 37258095
[TBL] [Abstract][Full Text] [Related]
4. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
Blood Pressure Lowering Treatment Trialists' Collaboration
Lancet; 2021 Sep; 398(10305):1053-1064. PubMed ID: 34461040
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R
Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
Blood Pressure Lowering Treatment Trialists' Collaboration
Lancet; 2021 May; 397(10285):1625-1636. PubMed ID: 33933205
[TBL] [Abstract][Full Text] [Related]
7. Fixed-Dose Combination Therapy for the Prevention of Cardiovascular Diseases in CKD: An Individual Participant Data Meta-Analysis.
Sepanlou SG; Mann JFE; Joseph P; Pais P; Gao P; Sharafkhah M; Roshandel G; Yusuf S; Malekzadeh R;
Clin J Am Soc Nephrol; 2023 Nov; 18(11):1408-1415. PubMed ID: 37550842
[TBL] [Abstract][Full Text] [Related]
8. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
[TBL] [Abstract][Full Text] [Related]
9. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
; Baigent C; Blackwell L; Collins R; Emberson J; Godwin J; Peto R; Buring J; Hennekens C; Kearney P; Meade T; Patrono C; Roncaglioni MC; Zanchetti A
Lancet; 2009 May; 373(9678):1849-60. PubMed ID: 19482214
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Steg PG; Bhatt DL; Simon T; Fox K; Mehta SR; Harrington RA; Held C; Andersson M; Himmelmann A; Ridderstråle W; Leonsson-Zachrisson M; Liu Y; Opolski G; Zateyshchikov D; Ge J; Nicolau JC; Corbalán R; Cornel JH; Widimský P; Leiter LA;
N Engl J Med; 2019 Oct; 381(14):1309-1320. PubMed ID: 31475798
[TBL] [Abstract][Full Text] [Related]
11. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials.
Rothwell PM; Cook NR; Gaziano JM; Price JF; Belch JFF; Roncaglioni MC; Morimoto T; Mehta Z
Lancet; 2018 Aug; 392(10145):387-399. PubMed ID: 30017552
[TBL] [Abstract][Full Text] [Related]
12. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Gaziano JM; Brotons C; Coppolecchia R; Cricelli C; Darius H; Gorelick PB; Howard G; Pearson TA; Rothwell PM; Ruilope LM; Tendera M; Tognoni G;
Lancet; 2018 Sep; 392(10152):1036-1046. PubMed ID: 30158069
[TBL] [Abstract][Full Text] [Related]
13. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
Bhatt DL; Steg PG; Mehta SR; Leiter LA; Simon T; Fox K; Held C; Andersson M; Himmelmann A; Ridderstråle W; Chen J; Song Y; Diaz R; Goto S; James SK; Ray KK; Parkhomenko AN; Kosiborod MN; McGuire DK; Harrington RA;
Lancet; 2019 Sep; 394(10204):1169-1180. PubMed ID: 31484629
[TBL] [Abstract][Full Text] [Related]
14. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
Zheng SL; Roddick AJ
JAMA; 2019 Jan; 321(3):277-287. PubMed ID: 30667501
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
[TBL] [Abstract][Full Text] [Related]
16. Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin.
McGrath E; O'Conghaile A; Eikelboom JW; Dinneen SF; Oczkowski C; O'Donnell MJ
Cerebrovasc Dis; 2011; 32(1):22-7. PubMed ID: 21576939
[TBL] [Abstract][Full Text] [Related]
17. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
Nazarzadeh M; Bidel Z; Canoy D; Copland E; Bennett DA; Dehghan A; Davey Smith G; Holman RR; Woodward M; Gupta A; Adler AI; Wamil M; Sattar N; Cushman WC; McManus RJ; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K;
Lancet Diabetes Endocrinol; 2022 Sep; 10(9):645-654. PubMed ID: 35878651
[TBL] [Abstract][Full Text] [Related]
19. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.
Sleem A; Effron MB; Stebbins A; Wruck LM; Marquis-Gravel G; Muñoz D; Re RN; Gupta K; Pepine CJ; Jain SK; Girotra S; Whittle J; Benziger CP; Farrehi PM; Knowlton KU; Polonsky TS; Roe MT; Rothman RL; Harrington RA; Jones WS; Hernandez AF
JAMA Cardiol; 2023 Nov; 8(11):1061-1069. PubMed ID: 37792369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
